PRESS RELEASE

Q3 2022 — Press release

Q3 2022PDF · 14 pages209 KB
News Release
____________________________________________________________________________________
FOR IMMEDIATE RELEASE
Merck Announces Third-Quarter 2022 Financial Results
• 	Third-Quarter Results Reflect Sustained Strong Business Momentum Across Key
Growth Drivers as Well as Investment and Progress in the Pipeline
• 	Third-Quarter 2022 Worldwide Sales Were $15.0 Billion, an Increase of 14% From
Third-Quarter 2021; LAGEVRIO Sales Were $436 Million; Growth Excluding LAGEVRIO
Was 10%; Growth Excluding LAGEVRIO and the Impact From Foreign Exchange Was
14%; Sales Growth Favorably Impacted by COVID-19 Recovery
o 	KEYTRUDA Sales Grew 20% to $5.4 Billion; Excluding the Impact From Foreign
Exchange, Sales Grew 26%
o 	GARDASIL/GARDASIL 9 Sales Grew 15% to $2.3 Billion; Excluding the Impact
From Foreign Exchange, Sales Grew 20%
• 	Third-Quarter 2022 GAAP EPS From Continuing Operations Was $1.28; Non-GAAP
EPS Was $1.85; GAAP and Non-GAAP EPS Include $0.22 of Charges Related to
Collaboration and Licensing Agreements with Moderna, Orna and Orion
• 	Announced Positive Top-line Results From Pivotal Phase 3 STELLAR Trial Evaluating
the Safety and Efficacy of Sotatercept
• 	2022 Continuing Operations Financial Outlook:
o 	Company Raises and Narrows Expected Full-Year 2022 Worldwide Sales To Be
Between $58.5 Billion and $59.0 Billion, Reflecting Full-Year Growth of 20% to
21%, Growth of Approximately 12% Excluding LAGEVRIO; Outlook Includes
Negative Impact From Foreign Exchange of Approximately 4%
o 	Company Lowers Expected Full-Year 2022 GAAP EPS To Be Between $5.68
and $5.73
o 	Company Raises and Narrows Expected Full-Year 2022 Non-GAAP EPS To Be
Between $7.32 and $7.37, Including Negative Impact From Foreign Exchange of
Approximately 4%

-- 1 of 14 --

- 2 -
RAHWAY, N.J., Oct. 27, 2022 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the third quarter of 2022.
“We continue to execute on our strategy, invest in leading-edge science and drive
innovation as our colleagues deliver meaningful value for patients – which in turn provides value
for our shareholders,” said Robert M. Davis, chief executive officer and president, Merck. “Our
third quarter results demonstrate exceptional revenue and underlying earnings growth and
sustained performance across our key growth drivers. Inspired by our purpose of saving and
improving lives around the world, I am confident we are well-positioned to continue to deliver
strong operational performance.”
Financial Summary
$ in millions, except EPS amounts
Third Quarter
2022 	2021 	Change
Change
Ex-
Exchange
Sales 	$14,959 	$13,154 	14% 	18%
GAAP net income1 	3,248 	4,567 	-29% 	-25%
Non-GAAP net income that excludes certain
items1,2* 	4,703 	4,525 	4% 	7%
GAAP EPS 	1.28 	1.80 	-29% 	-25%
Non-GAAP EPS that excludes certain items2* 	1.85 	1.78 	4% 	7%
*Refer to table on page 11.
Generally accepted accounting principles (GAAP) earnings per share (EPS) assuming
dilution was $1.28 for the third quarter of 2022. Non-GAAP EPS of $1.85 for the third quarter of
2022 excludes acquisition- and divestiture-related costs and restructuring costs, as well as
income and losses from investments in equity securities. In 2022, the company changed the
treatment of certain items for purposes of its non-GAAP reporting. Results for 2021 have been
recast to conform to the new presentation. For more information, refer to the Form 8-K filed by
the company on April 21, 2022.
Year-to-date results can be found in the attached tables.
1 Net income from continuing operations attributable to Merck & Co., Inc.
2 Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a
attached to this release. Non-GAAP results for 2021 have been recast to conform to presentation changes implemented in 2022.

-- 2 of 14 --

- 3 -
Cardiovascular pipeline highlights
• 	Merck announced positive results from its pivotal Phase 3 STELLAR trial evaluating
sotatercept, the company’s investigational activin receptor type IIA-Fc fusion protein, as
an add-on to stable background therapy for the treatment of adults with pulmonary
arterial hypertension. The trial met its primary efficacy outcome measure, demonstrating
a statistically significant and clinically meaningful improvement in six-minute walk
distance (6MWD) from baseline at 24 weeks, and eight out of nine secondary efficacy
outcome measures, including the outcome measure of proportion of participants
achieving multicomponent improvement [defined as improvement in 6MWD,
improvement in N-terminal pro-B-type natriuretic peptide level, and either improvement
in WHO Functional Class (FC) or maintenance of WHO FC II] and the outcome measure
of time to death or the first occurrence of a clinical worsening event. The
Cognitive/Emotional Impacts domain score of PAH-SYMPACT®, which was assessed
as the ninth and final secondary outcome measure, did not achieve statistical
significance. Results will be presented at an upcoming scientific congress.
• 	Merck received a Fast Track designation from the U.S. Food and Drug Administration
(FDA) for MK-2060, an investigational anticoagulant therapy for the reduction in risk of
major thrombotic cardiovascular events in patients with end-stage renal disease.
Oncology program highlights
• 	Merck announced clinical trial results for KEYTRUDA (pembrolizumab), the company’s
anti-PD-1 therapy, and Lynparza (olaparib), an oral poly (ADP-ribose) PARP inhibitor
being co-developed and co-commercialized with AstraZeneca, at the European Society
for Medical Oncology Congress 2022, including:
o 	Five-year overall survival (OS) data from the pivotal Phase 3 KEYNOTE-189 trial
(KEYTRUDA plus pemetrexed and either cisplatin or carboplatin) in patients with
metastatic nonsquamous non-small cell lung cancer (NSCLC) and the Phase 3
KEYNOTE-407 trial (KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel) in
patients with metastatic squamous NSCLC.
o 	In collaboration with Seagen and Astellas, the first presentation of data from
Cohort K of the Phase 1b/2 EV-103/KEYNOTE-869 trial evaluating Padcev
(enfortumab vedotin-ejfv) in combination with KEYTRUDA as first-line treatment
for patients with cisplatin-ineligible unresectable locally advanced or metastatic
urothelial cancer.

-- 3 of 14 --

- 4 -
o 	Seven-year OS data from the Phase 3 SOLO-1 trial evaluating Lynparza as
maintenance treatment in patients with advanced BRCA-mutated ovarian cancer,
following first-line platinum-based chemotherapy, and final OS results from the
Phase 3 PAOLA-1 trial evaluating Lynparza in combination with bevacizumab as
maintenance treatment in patients with advanced ovarian cancer who were
without evidence of disease after surgery or following response to platinum-
based chemotherapy. The results of both trials were clinically meaningful in
certain types of patients, but did not reach statistical significance.
• 	Merck announced that KEYTRUDA received four new approvals in Japan; KEYTRUDA
is now approved in Japan for 23 uses in 11 different types of cancer, plus microsatellite
instability-high (MSI-H) and tumor mutational burden-high solid tumors.
• 	Merck announced the following regulatory milestones for Lynparza:
o 	Priority review granted by the FDA for a supplemental New Drug Application for
Lynparza in combination with abiraterone and prednisone or prednisolone for
patients with metastatic castration-resistant prostate cancer (mCRPC), based on
results from the Phase 3 PROpel trial. The Prescription Drug User Fee Act
(PDUFA) date is in the fourth quarter of 2022.
o 	Approved in the European Union (EU) and Japan as adjuvant treatment for
patients with germline BRCA-mutated, HER2-negative high-risk early breast
cancer, based on results from the Phase 3 OlympiA trial.
o 	Approved in China as first-line maintenance treatment with bevacizumab for
patients with homologous recombination deficient-positive advanced ovarian
cancer, based on results from the Phase 3 PAOLA-1 trial.
• 	Merck provided updates on three Phase 3 trials: KEYNOTE-412, KEYNOTE-921
and LEAP-002.
Vaccines program highlights
• 	Merck announced European Commission approval of an expanded indication for
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include active
immunization for the prevention of invasive disease, pneumonia and acute otitis media
caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and
adolescents from 6 weeks to less than 18 years of age.
• 	Merck received approval from China’s National Medical Products Administration to
expand the use of GARDASIL 9 [Human Papillomavirus (HPV) 9-valent Vaccine,

-- 4 of 14 --

- 5 -
Recombinant] for use in girls and women ages 9 to 45. The vaccine was previously
approved for use in women ages 16 to 26.
Infectious diseases pipeline highlights
• 	Merck will initiate a new Phase 3 clinical program with islatravir for the treatment of
people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral
combination of doravirine 100 mg and islatravir (DOR/ISL) 0.25 mg.
• 	Merck and Gilead Sciences will resume the Phase 2 clinical trial evaluating an
investigational oral once-weekly combination treatment regimen of islatravir and Gilead’s
lenacapavir in adults with HIV-1 infection who are virologically suppressed.
• 	Merck and Ridgeback Biotherapeutics (Ridgeback) provided an update on a preliminary
analysis of the University of Oxford’s open label prospective real-world evidence study,
PANORAMIC, of LAGEVRIO (molnupiravir).
Business development highlights
• 	Merck and Moderna, Inc. (Moderna) announced that Merck has exercised its option to
jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940
pursuant to the terms of its existing collaboration and license agreement. mRNA-
4157/V940 is currently being evaluated in combination with KEYTRUDA as adjuvant
treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted
by Moderna.
• 	Merck and Orna Therapeutics (Orna) announced a collaboration agreement to discover,
develop and commercialize multiple programs, including vaccines and therapeutics in
the areas of infectious diseases and oncology. This collaboration will combine Merck’s
expertise in nucleic acid biology, clinical development, and manufacturing with Orna’s
circular RNA technology.
• 	Merck and Orion Corporation (Orion) formed a global development and
commercialization agreement for Orion’s investigational candidate ODM-208/MK-5684
and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in
steroid production. ODM-208/MK-5684 is an oral, non-steroidal inhibitor of CYP11A1
currently being evaluated in a Phase 2 clinical trial for the treatment of patients with
mCRPC.

-- 5 of 14 --

- 6 -
• 	Merck acquired Vence, an innovator in virtual fencing for rotational grazing and livestock
management, which complements Merck Animal Health’s broad portfolio of veterinary
pharmaceuticals, vaccines and animal intelligence solutions.
Environmental, Social and Governance (ESG) highlights
• 	Merck issued its 2021/2022 ESG Progress Report, highlighting the company’s
performance and progress in ESG efforts across four main focus areas: Access to
Health, Employees, Environmental Sustainability and Ethics & Values. These efforts
come as part of a long-standing commitment to operating responsibly and creating value
for patients and shareholders.
• 	Merck launched the Alliance for Equity in Cancer Care, an initiative to advance equity in
cancer care in the U.S. by helping patients living in underserved communities receive
timely access to high-quality, culturally responsive care.
• 	Merck was recognized on Fortune’s 2022 Change the World list for its work to make
HPV vaccines broadly available in underserved countries through partnerships and
manufacturing investments.

-- 6 of 14 --

- 7 -
Third-quarter revenue performance
The following table reflects sales of the company’s top pharmaceutical products, as well
as sales of Animal Health products.
Third Quarter
$ in millions 	2022 	2021 	Change
Change Ex-
Exchange
Total Sales 	$14,959 	$13,154 	14% 	18%
Pharmaceutical 	12,963 	11,496 	13% 	19%
KEYTRUDA 	5,426 	4,534 	20% 	26%
GARDASIL / GARDASIL 9 	2,294 	1,993 	15% 	20%
JANUVIA / JANUMET 	1,133 	1,339 	-15% 	-9%
PROQUAD, M-M-R II and
VARIVAX 	668 	661 	1% 	3%
LAGEVRIO 	436 	0 	- 	-
BRIDION
Lynparza*
423
284
369
246
15%
16%
22%
23%
ROTATEQ 	256 	227 	12% 	16%
Lenvima* 	202 	188 	7% 	11%
SIMPONI 	173 	203 	-15% 	-2%
Animal Health 	1,371 	1,417 	-3% 	4%
Livestock 	829 	864 	-4% 	4%
Companion Animals 	542 	553 	-2% 	4%
Other Revenues** 	625 	241 	*** 	41%
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including
revenue-hedging activities.
***>100%
Pharmaceutical revenue
Third-quarter pharmaceutical sales increased 13% to $13.0 billion. Pharmaceutical sales
growth in the third quarter was 9% excluding LAGEVRIO sales and 15% excluding LAGEVRIO
sales and the impact of foreign exchange, primarily driven by oncology, vaccines and hospital
acute care products. The COVID-19 pandemic unfavorably affected sales in the third quarter of
2021 by approximately $350 million, which favorably impacted the growth rate in the third
quarter of 2022.
Growth in oncology was largely driven by higher sales of KEYTRUDA, which rose 20%
to $5.4 billion in the quarter. Global sales growth of KEYTRUDA reflects continued strong
momentum from metastatic indications including certain types of NSCLC, renal cell carcinoma,
head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC) and MSI-H
cancers, and increased uptake across recent earlier-stage launches including certain types of
neoadjuvant/adjuvant TNBC in the U.S.

-- 7 of 14 --

- 8 -
Growth in vaccines was primarily driven by higher combined sales of GARDASIL
(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and
GARDASIL 9 vaccines to prevent certain cancers and other diseases caused by HPV. Third-
quarter GARDASIL/GARDASIL 9 sales grew 15% to $2.3 billion, primarily driven by strong
demand outside of the U.S., particularly in China, which also benefited from increased supply.
Additionally, higher sales in the U.S. reflect public sector buying patterns. Growth in vaccines
was partially offset by lower sales of PNEUMOVAX 23 (pneumococcal vaccine polyvalent), a
vaccine to help prevent pneumococcal disease, which declined 53% to $131 million primarily
reflecting lower U.S. demand as the market continues to shift toward newer adult pneumococcal
conjugate vaccines.
Growth in hospital acute care reflects higher demand globally for BRIDION
(sugammadex) injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade
induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ages 2
years and older undergoing surgery. Sales increased 15% to $423 million, primarily due to an
increase in its share among neuromuscular blockade reversal agents and an increase in
surgical procedures. Growth in hospital acute care also reflects higher sales of ZERBAXA
(ceftolozane and tazobactam), a combination cephalosporin antibacterial and beta-lactamase
inhibitor for the treatment of adults with certain bacterial infections. Sales of $43 million resulted
from the phased resupply initiated in the fourth quarter of 2021, which has been completed in
2022.
Pharmaceutical sales growth was partially offset by lower combined sales of JANUVIA
(sitagliptin) and JANUMET (sitagliptin and metformin HCI), which declined 15% to $1.1 billion,
primarily reflecting lower demand and pricing in certain international markets as a result of
generic competition, particularly in Europe, and lower demand in the U.S. The company lost
market exclusivity for JANUVIA and JANUMET in China in July and in the EU in September,
although JANUMET currently continues to have exclusivity in certain European markets.
Animal Health revenue
Animal Health sales totaled $1.4 billion for the third quarter of 2022, a decline of 3%
compared with the third quarter of 2021. Excluding the unfavorable effect from foreign
exchange, Animal Health sales grew 4% primarily reflecting higher pricing. Sales of livestock
products also reflect higher demand for poultry products. Sales of companion animal products
also reflect higher demand for the BRAVECTO (fluralaner) parasiticide line of products, partially
offset by supply constraints for certain vaccines.

-- 8 of 14 --

- 9 -
Third-quarter expense information
The tables below present selected expense information.
$ in millions
Third Quarter 2022 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss from
Investments
in Equity
Securities
Non-
GAAP2
Cost of sales 	$3,934 	$446 	$54 	$- 	$3,434
Selling, general and
administrative 	2,520 	22 	26 	- 	2,472
Research and
development 	4,399 	902 	1 	- 	3,496
Restructuring costs 	94 	- 	94 	- 	-
Other (income)
expense, net 	429 	(26) 	- 	350 	105
Third Quarter 2021
Cost of sales 	$3,450 	$346 	$48 	$- 	$3,056
Selling, general and
administrative 	2,336 	61 	5 	- 	2,270
Research and
development 	2,445 	48 	8 	- 	2,389
Restructuring costs 	107 	- 	107 	- 	-
Other (income)
expense, net 	(450) 	(10) 	- 	(684) 	244
GAAP expense, EPS and related information
Gross margin was 73.7% for the third quarter of 2022 compared to 73.8% for the third
quarter of 2021. The decrease primarily reflects the impacts of higher revenue from third-party
manufacturing arrangements and sales of LAGEVRIO, both of which have lower gross margins,
as well as higher acquisition- and divestiture-related costs. The gross margin decline was
largely offset by the favorable effects of product mix and foreign exchange.
Selling, general and administrative (SG&A) expenses were $2.5 billion in the third
quarter of 2022, an increase of 8% compared to the third quarter of 2021. The increase primarily
reflects higher administrative costs, including compensation and benefit costs, as well as higher
promotional spending, partially offset by the favorable impact of foreign exchange.
Research and development (R&D) expenses were $4.4 billion in the third quarter of
2022 compared to $2.4 billion in the third quarter of 2021. The increase primarily reflects $887
3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a
result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value
measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs related to
acquisitions and divestitures.

-- 9 of 14 --

- 10 -
million of intangible asset impairment charges related to the ArQule, Inc. acquisition, charges
related to collaboration and licensing agreements with Moderna, Orna and Orion and higher
clinical development spending.
Other (income) expense, net, was $429 million of expense in the third quarter of 2022
compared to $450 million of income in the third quarter of 2021, primarily due to net unrealized
losses from investments in equity securities in the third quarter of 2022, compared to net
unrealized income from investments in equity securities in the third quarter of 2021. Other
(income) expense, net, in the third quarter of 2022 also reflects lower pension costs compared
to the third quarter of 2021.
The effective income tax rate was 9.2% for the third quarter of 2022 compared to 13.2%
in the third quarter of 2021.
GAAP EPS was $1.28 for the third quarter of 2022 compared to $1.80 for the third
quarter of 2021.
Non-GAAP expense, EPS and related information
Non-GAAP gross margin was 77.0% for the third quarter of 2022 compared to 76.8% for
the third quarter of 2021. The increase in non-GAAP gross margin primarily reflects the
favorable effects of product mix and foreign exchange, largely offset by the impacts of higher
revenue from third-party manufacturing arrangements and sales of LAGEVRIO, both of which
have lower gross margins.
Non-GAAP SG&A expenses were $2.5 billion in the third quarter of 2022, an increase of
9% compared to the third quarter of 2021. The increase primarily reflects higher administrative
costs, including compensation and benefit costs, as well as higher promotional spending,
partially offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $3.5 billion in the third quarter of 2022 compared to
$2.4 billion in the third quarter of 2021. The increase primarily reflects charges related to
collaboration and licensing agreements with Moderna, Orna and Orion and higher clinical
development spending.
Non-GAAP other (income) expense, net, was $105 million of expense in the third quarter
of 2022 compared to $244 million of expense in the third quarter of 2021, reflecting lower
pension costs.
The non-GAAP effective income tax rate was 13.6% for the third quarter of 2022
compared to 12.8% in the third quarter of 2021.

-- 10 of 14 --

- 11 -
Non-GAAP EPS was $1.85 for the third quarter of 2022 compared to $1.78 for the third
quarter of 2021.
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Financial outlook
Beginning in 2022, Merck no longer excludes expenses for upfront and milestone
payments related to collaboration and licensing agreements, or charges related to pre-approval
assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results.
Historically, the company excluded these charges to the extent they were considered by the
company to be significant to the results of a particular period. These changes were made to
align with views expressed by the U.S. Securities and Exchange Commission. Prior periods
have been recast to reflect this change. For 2021, non-GAAP results have been recast to
include $1.7 billion of incremental R&D expense, resulting in revised full-year 2021 EPS of
$5.37.
Full-year 2022 GAAP and non-GAAP results include $690 million of incremental R&D
expense, recorded in the third quarter of 2022, for collaboration and licensing agreements with
Moderna, Orna and Orion which negatively impacts expected full-year EPS by $0.22.
As an on-going practice, the financial outlook will not include significant potential
business development transactions.
Third Quarter
$ in millions, except EPS amounts 	2022 	2021
EPS
GAAP EPS 	$1.28 	$1.80
Difference 	0.57 	(0.02)
Non-GAAP EPS that excludes items listed below2 	$1.85 	$1.78
Net Income
GAAP net income1 	$3,248 	$4,567
Difference 	1,455 	(42)
Non-GAAP net income that excludes items listed below1,2 	$4,703 	$4,525
Decrease (Increase) in Net Income Due to Excluded Items:
Acquisition- and divestiture-related costs3 	$1,344 	$445
Restructuring costs 	175 	168
Loss (income) from investments in equity securities 	350 	(684)
Net decrease (increase) in income before taxes 	1,869 	(71)
Estimated income tax (benefit) expense 	(414) 	29
Decrease (increase) in net income 	$1,455 	$(42)

-- 11 of 14 --

- 12 -
Merck continues to experience strong global momentum across its key pillars of growth,
particularly in oncology and vaccines. As a result, Merck is raising and narrowing its full-year
outlook for sales and non-GAAP EPS, despite a negative impact from foreign exchange.
At mid-October 2022 exchange rates, Merck expects sales growth of 20% to 21% in
2022, with full-year sales estimated to be between $58.5 billion and $59.0 billion, including a
negative impact from foreign exchange of approximately 4%, including a less than 1%
incremental negative impact from prior sales outlook. Excluding LAGEVRIO, Merck expects
sales growth of approximately 12% for full-year 2022.
Merck expects its full-year non-GAAP effective income tax rate to be approximately
14%.
Merck is lowering its expected full-year 2022 GAAP EPS to be between $5.68 and
$5.73.
Merck is raising and narrowing its expected full-year 2022 non-GAAP EPS to be
between $7.32 and $7.37, including a negative impact from foreign exchange of approximately
4% at mid-October exchange rates. Operational strength of approximately $0.20 is partially
offset by the following negative impacts, which were not reflected previously in the outlook:
o 	An option payment to Moderna of $250 million
o 	A less than 1% incremental impact from foreign exchange
The non-GAAP range excludes acquisition- and divestiture-related costs and costs
related to restructuring programs as well as income and losses from investments in equity
securities.
The company is narrowing its expected full year sales range of LAGEVRIO to be
between $5.2 billion and $5.4 billion. Merck shares profits equally with its partner, Ridgeback,
which is reflected in cost of sales.
The following table summarizes the company’s full-year 2022 financial outlook.
GAAP 	Non-GAAP2
Sales 	$58.5 to $59.0 billion 	$58.5 to $59.0. billion*
Operating expenses 	$22.5 to $22.9 billion 	$21.3 to $21.7 billion
Effective tax rate 	Approximately 11% 	Approximately 14%
EPS** 	$5.68 to $5.73 	$7.32 to $7.37
*The company does not have any non-GAAP adjustments to sales.
**EPS outlook for 2022 assumes a share count (assuming dilution) of approximately 2.54 billion shares.

-- 12 of 14 --

- 13 -
A reconciliation of anticipated full-year 2022 GAAP EPS to non-GAAP EPS and the
items excluded from non-GAAP EPS are provided in the table below.
$ in millions, except EPS amounts 	Full-Year 2022
GAAP EPS 	$5.68 to $5.73
Difference 	$1.64
Non-GAAP EPS that excludes items listed below2 	$7.32 to $7.37
Acquisition- and divestiture-related costs
Restructuring costs
(Income) loss from investments in equity securities
$3,400
600
1,350
Net decrease (increase) in income before taxes 	5,350
Estimated income tax (benefit) expense 	(1,175)
Decrease (increase) in net income 	$4,175
Earnings conference call
Investors, journalists and the general public may access a live audio webcast of the call
Thursday, Oct. 27, at 8:00 a.m. ET via this weblink. A replay of the webcast, along with the
sales and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available at www.merck.com.
Participants may join the call by dialing (877) 692-8955 (USA Toll-Free) or (243) 720-
6979 (USA Caller Paid). If you are calling from other countries, visit this weblink. All dial-in
participants can use the access code 9646315. Journalists who wish to ask questions are
requested to contact a member of Merck’s Media Relations team.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us
on Twitter, Facebook, Instagram, YouTube and LinkedIn.

-- 13 of 14 --

- 14 -
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the
impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of international economies
and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).
###
Media Contacts: 	Melissa Moody 	Investor Contacts: 	Peter Dannenbaum
(215) 407-3536 	(908) 740-1037
Johanna Herrmann
(617) 216-6029
Steven Graziano
(908) 740-6582

-- 14 of 14 --